best peptides FAQ

Growth hormone is lipolytic. It promotes fat oxidation by increasing hormone-sensitive lipase activity in adipocytes. Running a GH secretagogue during a caloric deficit preserves lean mass and accelerates fat loss compared to diet alone. MK-677 increases appetite significantly, which complicates adherence to a deficit, making GHRP-2 the better choice during weight cuts. Dose GHRP-2 post-training when appetite suppression from exercise is strongest, and avoid dosing first thing in the morning when hunger is already elevated.

MOTS-C operates at the mitochondrial level. Effects are cumulative, not immediate. Most researchers report measurable improvements in sustained focus after 2–3 weeks at 10mg three times weekly, once mitochondrial biogenesis upregulates. If you feel nothing after one injection, that's expected. The peptide isn't a stimulant. It's restoring cellular machinery that takes time to rebuild. Continue the protocol for at least four weeks before evaluating efficacy.

Semax and Selank act on different neurotransmitter systems than amphetamine-based ADHD medications, so direct pharmacological interaction is unlikely. But this isn't medical advice. Stimulants work through dopamine and norepinephrine release; Semax works through acetylcholine preservation. The concern is additive cognitive load without corresponding metabolic support. If combining, prioritize MOTS-C for mitochondrial support and monitor for overstimulation. Consult your prescribing physician before stacking any peptide with prescription CNS medications.

IGF-1 analogs activate insulin receptors at approximately 10% the affinity of insulin itself. At doses above 60mcg daily, this cross-reactivity can lower blood glucose enough to cause shakiness, sweating, or mental fog 30–60 minutes post-injection. Immediate solution: consume 20–30g fast-acting carbohydrate (dextrose, fruit) within 15 minutes of injection. Long-term solution: reduce IGF-1 LR3 dose to 40mcg daily and administer it post-workout when insulin sensitivity is highest and glucose disposal into muscle is active. This minimizes hypoglycemia risk while preserving anabolic signaling.

Verify the peptide was stored correctly and hasn't exceeded its post-reconstitution stability window. Degraded thymosin alpha-1 loses immune-modulating capacity within 4–6 weeks if stored above 8°C. If storage was correct, the patient may have unaddressed root causes (chronic mold exposure, undiagnosed infections, ongoing gut dysbiosis) that prevent immune normalization. Peptides amplify the body's repair mechanisms. They can't override active pathogenic load or environmental toxin exposure.

Rotate injection sites across abdomen, thighs, and upper arms. Repetitive injection in the same area causes localized inflammatory responses and lipodystrophy. Ensure the peptide reaches room temperature before injection (cold peptides cause more discomfort) and inject slowly over 5–10 seconds. If reactions persist despite rotation, the issue is likely the reconstitution solution. Switch from standard bacteriostatic water to bacteriostatic sodium chloride 0.9%, which has lower osmotic irritation potential.

BPC-157 demonstrates systemic effects even when injected away from the injury site. Subcutaneous injection into abdominal fat produces measurable VEGF upregulation and collagen synthesis at distant tissue sites through circulation. For localized effect, inject 250mcg subcutaneously as close to the affected area as anatomy allows (deltoid, near rotator cuff insertion points), but avoid injecting directly into inflamed tissue. Systemic administration works. Local administration may accelerate effect onset by 20–30%, but the peptide reaches injury sites regardless of injection location.

No, but your choice shifts. BPC-157's angiogenic window closes by day 14–21 when new capillary formation plateaus, so starting it at week 3 provides limited additional benefit. TB-500 remains effective through week 8 because fibroblast migration and collagen deposition continue well into the remodelling phase. GHK-Cu becomes your primary target starting week 3. This is when collagen remodelling begins and organised fibril alignment determines final scar strength and appearance. Late-stage peptide use focuses on optimising what has already healed rather than accelerating initial closure.

Stacking more than two peptides simultaneously increases the risk of unintended interactions and makes it impossible to isolate which compound is driving results or side effects. Start with one peptide for your highest-priority bottleneck, run it for 4–6 weeks, measure outcomes, then add a second peptide if needed. Avoid stacking peptides with overlapping mechanisms. Combining MK-677 with GHRP-2 doesn't produce additive GH release, it just increases the chance of elevated cortisol or blood glucose. The Body Recomp Bundle combines peptides with complementary rather than redundant pathways for this exact reason.

Increase frequency to three times daily rather than increasing dose. BPC-157 has a short half-life (approximately 4 hours) and more frequent dosing maintains higher steady-state plasma levels. If no biomarker improvement appears after 8 weeks at optimized frequency, the underlying pathology may not be angiogenesis-limited. Consider switching to thymosin beta-4, which addresses fibroblast migration through different signaling pathways.

GHK-Cu's senolytic effects are subtle and cumulative. There's no acute response like pharmaceutical senolytics produce. If SA-β-gal staining or inflammatory biomarkers (IL-6, hsCRP) haven't shifted after 8 weeks at 5–10mg subcutaneous 3× weekly, the issue is likely bioavailability or senescent cell burden baseline. Copper peptides require adequate copper cofactor availability. Serum copper below 70 μg/dL blunts the response. Consider measuring baseline inflammatory markers (IL-6, TNF-α, hsCRP) before starting and retesting at 12 weeks rather than relying on subjective assessment.

Do not administer immune-stimulating peptides like thymosin alpha-1 or LL-37 during acute infection when cytokine levels already exceed homeostatic range. The therapeutic window opens 7–14 days after symptom onset, once viral load or bacterial burden has resolved but before chronic immune suppression establishes. Premature administration during active inflammation compounds cytokine-mediated tissue damage rather than supporting resolution. This is why Phase II trials for sepsis used Tα1 as adjunctive therapy after initial stabilization, not during cytokine storm.

Combine Humanin and SS-31 in a protective protocol targeting both apoptotic prevention and membrane stabilization. Humanin at 2–5 mg daily prevents stress-induced mitochondrial destruction, while SS-31 at 1–2 mg/kg twice weekly stabilizes existing cardiolipin structures that would otherwise deteriorate with age. This combination mirrors the approach used in gerontology research focused on healthspan extension. Preventing both acute mitochondrial loss (Humanin) and chronic structural decay (SS-31). The protocol becomes particularly relevant after age 50, when endogenous Humanin levels drop below the threshold required for adequate mitochondrial protection.

Use MOTS-c at dosing ranges established in exercise physiology studies: 5–15 mg administered 30–60 minutes before resistance training or endurance exercise. MOTS-c's nuclear translocation is triggered by metabolic stress. Its effect amplifies when combined with ATP-depleting activity. Research shows that MOTS-c administration without concurrent exercise produces minimal mitochondrial biogenesis, whereas the combination increases PGC-1α expression by 340% compared to exercise alone. The peptide's half-life is approximately 2–3 hours, making pre-exercise timing critical for maximizing AMPK activation during the training window.

MK-677 at 25 mg orally once daily is the standard protocol. The 24-hour half-life maintains elevated IGF-1 throughout the day without requiring multiple injections, and the two-year trial data published in JCEM showed no tachyphylaxis. The GH response remained consistent across 104 weeks of continuous dosing. Warn subjects about increased appetite in the first 2–4 weeks (it's a ghrelin mimetic) and monitor fasting glucose monthly. Insulin sensitivity decreases slightly at doses above 25 mg daily, though the effect is subclinical in healthy populations. Oral administration eliminates reconstitution errors and injection-site variability that plague long-term injectable peptide studies.

Epitalon's effects plateau after initial telomere elongation because cells reach a homeostatic set point and downregulate TERT expression—this is expected, not a failure. If repeat cycles produce no additional lengthening, the realistic interpretation is that your cells have reached their genetically determined telomere equilibrium. Continuing administration won't override that set point. The alternative strategy: address oxidative and metabolic factors with humanin or MOTS-c to slow subsequent attrition rather than attempting further elongation.

High oxidative stress accelerates telomere shortening even when current length is normal—the damage is cumulative and forward-looking. Mitochondrial peptides (humanin, MOTS-c) address the root cause (excess ROS production) before telomeres reach critical shortness. This is prevention rather than rescue. Biomarkers to track: urinary 8-oxo-dG (oxidative DNA damage), serum GSH/GSSG ratio (antioxidant capacity), and serum humanin levels (often low in metabolic syndrome and type 2 diabetes).

Telomerase is active in 85–95% of human cancers, which is why chronic reactivation in aging tissues raises theoretical oncogenic risk. Short-term epitalon use (10–20 days) likely poses minimal risk because pre-cancerous cells require multiple genetic hits beyond telomerase to progress to malignancy. The concern is cumulative: repeated cycles over years may allow incipient tumors to escape senescence barriers. No human longevity data exists to quantify this risk—anyone using telomerase-activating peptides long-term is in uncharted territory.

Combine ipamorelin (100 mcg) + CJC-1295 no DAC (30 mcg) administered 2–3 times daily, timed to coincide with natural GH pulse windows (pre-sleep, post-exercise, early morning). Ipamorelin initiates the pulse through GHS-R1a activation; CJC-1295 amplifies and extends it through GHRH receptor stimulation. This combination produces GH pulses that mirror endogenous secretion in amplitude and duration. Far closer to physiological rhythm than continuous GH infusion or DAC-modified peptides. Dose both peptides from the same syringe to reduce injection frequency; stability testing shows no degradation when mixed in bacteriostatic water for up to 14 days at 2–8°C.

FOXO4-DRI becomes the priority intervention before other mitochondrial peptides will produce meaningful results. Senescent cells secrete IL-6, IL-8, and TNF-α that directly inhibit PGC-1α transcription. Administering MOTS-c or SS-31 in a high-senescence environment is like trying to fill a leaking bucket. FOXO4-DRI at 5 mg/kg for a 2–4 week clearance cycle eliminates the inflammatory burden first, allowing mitochondrial biogenesis and repair pathways to function without constant suppression. Researchers typically wait 4–6 weeks after senolytic treatment before introducing biogenesis-focused peptides, giving the tissue environment time to stabilize.